Le Lézard
Classified in: Health
Subject: MRR

Smart Insulin Pen Market to grow US$ 237.1 Mn by end of 2028, Says Coherent Market Insights


SEATTLE, Dec. 2, 2021 /PRNewswire/ -- According to latest report, the global smart insulin pen market is estimated to account for US$ 237.1 Mn in terms of value by the end of 2028.

Coherent Market Insights

A smart insulin pen can be used to inject insulin, a vital hormone for people who have diabetes. Most smart insulin pens have built-in sensors on their cap. The data can be transmitted to your smartphone. These features can prevent over- or under-dosing, which can be dangerous for people with diabetes.

Several studies have evaluated the benefits of these devices. For instance, the use of a smart insulin pen can improve adherence to diabetes management and patient satisfaction. The use of connected smart insulin pens in the United States and other countries has increased. Many studies have shown that patients are more confident with the use of these devices compared to other devices. Additionally, the use of connected smart pens can help simplify documentation and improve communication between health care providers and patients.

Request for Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/3436

Market Drivers:

Approval and launch of new products is expected to propel growth of the global smart insulin pen market over the forecast period. For instance, in December 2019, Tandem Diabetes Care, Inc. received the U.S. Food and Drug Administration clearance for its t:slim X2 insulin pump with Control-IQ technology, an advanced hybrid-closed loop feature.

Moreover, high prevalence of diabetes is also expected to aid in growth of the global smart insulin pen market. For instance, according to International Diabetes Federation's IDF Diabetes Atlas 2019 Edition, the numbers of adults with diabetes in the U.S. was 31.0 million.

Market Opportunities:

Development and launch of integrated diabetes solutions is expected offer lucrative growth opportunities for players in the global smart insulin pen market. For instance, in October 2019, Tandem Diabetes Care Inc. partnered with Abbott Laboratories to develop and commercialize integrated diabetes solutions that combine Abbott's glucose sensing technology with Tandem's insulin delivery systems.

Moreover, launch of personalized automated insulin delivery systems is also expected offer lucrative growth opportunities for players in the global smart insulin pen market. For instance, in February 2020, Abbott Laboratories partnered with Insulet Corporation to integrate Abbott's glucose sensing technology with Insulet's next-generation tubeless system, the Omnipod Horizon Automated Insulin Delivery System (Omnipod Horizon System), to offer personalized automated insulin delivery and care for people living with diabetes.

Buy This Latest Premium Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/3436

Market Trends:

Major players operating in the global smart insulin pen market are focused on offering generic versions of products to enhance their market share. For instance, in January 2020, Eli Lilly and Company announced its plans to offer half-price generic versions of its fast-acting Humalog Junior KwikPen insulin and Humalog Mix75/25 KwikPen, which contains a mix of fast- and intermediate-acting insulin by mid-April 2020.

Major players operating in the global smart insulin pen market are focused on adopting partnership strategies to enhance their market share. For instance, in December 2019, BIOCORP, a medical devices and smart drug delivery systems developer based in France, partnered with SANOFI for the use of Mallya technology, a connected device for insulin pens.

Competitive Landscape:

Major players operating in the global smart insulin pen market include, Companion Medical Inc., Digital Medics Pty. Ltd., Emperra GmbH E-Health Technologies, and Novo Nordisk.

Major players operating in the global smart insulin pen market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2021, Medtronic plc received CE Mark for expanded functionality of the company's InPen smart2 insulin pen for multiple daily injections. The company also announced CE Mark for its Guardian 4 sensor, which requires no fingersticks1 for calibration or diabetes treatment decisions.

Market Segmentation:

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/3436 

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contact Us:

Mr. Shah
Senior Client Partner ? Business Development
Coherent Market Insights
Phone: 
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com 
Website: https://www.coherentmarketinsights.com 
Follow Us: LinkedInTwitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg  


These press releases may also interest you

at 04:00
Based in Augusta, Georgia, USA, Jinfiniti Precision Medicine is dedicated to increasing human health and lifespan by providing a range of rapid screening services to biomedical research institutions, nutraceutical companies, the longevity industry,...

at 04:00
The Celiac Disease Foundation, the nation's leading patient advocacy organization for celiac disease, announces its newest appointee, Casey Guber, to its Board of Directors. The officers for 2022 are Chair Adrienne Bender, Vice Chair John Wagner,...

at 03:46
Mentice AB (STO: MNTC) announces that the company will present its year-end report via a webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson. To register for the...

at 03:41
Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international medical cannabis pharmaceutical company trading on AQSE Growth Market, is pleased to announce the appointment of Dr. Herbert Fritsche to the Board of...

at 03:01
Nova Mentis Life Science Corp. ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the Company...

at 03:00
SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has appointed Professor Michael J. Econs, MD as Clinical Advisor. Distinguished Professor of Medicine and Medical and Molecular Genetics at...



News published on 2 december 2021 at 13:30 and distributed by: